Selecta Biosciences Inc (SELB)-製薬・医療分野:企業M&A・提携分析

GlobalDataが発行した調査報告書(DATA8013309)
◆英語タイトル:Selecta Biosciences Inc (SELB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013309
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:63
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥28,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥57,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥85,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Selecta Biosciences Inc (Selecta Biosciences) is a clinical-stage biopharmaceutical company which develops immunotherapies and vaccines to prevent and treat disease. The company’s pipeline products include SEL-212, SELA-070, SEL-701, LMB-100 and others. Its synthetic vaccine particle (SVP) technology platform can enable a novel approach for selectively targeting the immune system to treat and prevent rare and serious diseases. Selecta Biosciences develops products for the treatment of infections, central nervous system diseases, cancer, allergies, cardiovascular diseases, autoimmunity, metabolic diseases, asthma and acute and chronic inflammatory conditions. The company collaborates with pharma companies to develop drugs for allergy and autoimmune diseases. Selecta Biosciences is headquartered in Watertown, Massachusetts, the US.

Selecta Biosciences Inc (SELB) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Selecta Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Selecta Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Selecta Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Selecta Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Selecta Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Selecta Biosciences Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Selecta Biosciences Raises USD38 Million in Series E Financing 12
Selecta Biosciences Raises More than USD20 Million in Venture Financing 14
Selecta Biosciences Raises USD4.4 Million in Venture Financing 16
Selecta Biosciences Raises USD6 Million in Venture Financing 17
Selecta Biosciences Raises USD5.3 Million in Venture Financing 18
Selecta Biosciences Secures US$47 Million In Series D Financing Round 19
Partnerships 21
Selecta Biosciences Enters into Research Agreement with Genethon 21
Selecta Biosciences and Juvenile Diabetes Research Foundation Enter into Co-Development Agreement with Sanofi 22
Juvenile Diabetes Research Foundation Enters Into Research Collaboration With Selecta Biosciences 23
Licensing Agreements 24
Selecta Biosciences Enters into Licensing Agreement with National Cancer Institute 24
Spark Therapeutics Enters into Licensing Agreement with Selecta Biosciences 26
Selecta Biosciences Enters into Licensing Agreement with Massachusetts Eye and Ear Infirmary 28
Selecta Biosciences Enters into Licensing Agreement with 3SBio for Pegsiticase 29
Selecta Biosciences Exercises Option for Licensing Agreement with Sanofi 30
Equity Offering 31
Selecta Biosciences Files Registration Statement to Raise Funds through Public Offering of Shares 31
Selecta Biosciences to Raise USD50 Million in Private Placement of Shares and Warrants 32
Selecta Biosciences to Raise USD5 Million in Private Placement of Shares 33
Selecta Biosciences Raises USD70 Million in IPO 35
Selecta Biosciences Inc – Key Competitors 37
Selecta Biosciences Inc – Key Employees 38
Selecta Biosciences Inc – Locations And Subsidiaries 39
Head Office 39
Other Locations & Subsidiaries 39
Recent Developments 40
Financial Announcements 40
Nov 07, 2017: Selecta Biosciences Announces Third Quarter 2017 Financial Results and Provides Corporate Update 40
Aug 11, 2017: Selecta Biosciences Announces Second Quarter 2017 Financial Results and Provides Corporate Update 43
May 11, 2017: Selecta Biosciences Announces First Quarter 2017 Financial Results and Provides Corporate Update 45
Mar 27, 2017: Selecta Biosciences Announces Fourth Quarter and Year End 2016 Financial Results and Provides Corporate Update 47
Nov 10, 2016: Selecta Biosciences Announces Third Quarter 2016 Financial Results 50
Aug 09, 2016: Selecta Biosciences Announces Second Quarter 2016 Financial Results and Provides Corporate Update 52
Corporate Communications 54
Oct 26, 2017: Selecta Biosciences Announces Important Additions to Senior Leadership Team 54
Aug 01, 2016: Selecta Biosciences Appoints Timothy C. Barabe to Board of Directors 55
Product News 56
Aug 01, 2016: Selecta Biosciences Announces Publication in Nature Nanotechnology Describing Novel Approach for Improving the Efficacy and Safety Profile of Biologic Drugs 56
07/19/2016: Selecta Biosciences Announces Gene Therapy Programs for Two Rare Genetic Metabolic Disorders 57
05/01/2017: Selecta Biosciences Announces Presentations at the 20th Annual Meeting of the American Society of Gene & Cell Therapy 58
Clinical Trials 59
May 15, 2017: Selecta Biosciences Announces New Preclinical Gene Therapy Data at the Annual Meeting of the American Society of Gene & Cell Therapy 59
May 11, 2017: Selecta Biosciences Commences Dosing in Phase 1 Clinical Trial of Nicotine Vaccine for Smoking Cessation and Relapse Prevention 60
Feb 06, 2017: Selecta Biosciences Presents Preclinical Data Regarding SVP-Enabled Celiac Disease Treatment 61
Feb 06, 2017: Selecta Biosciences Presents Preclinical Data Regarding SVP-Enabled Peanut Allergy Therapeutic Vaccine 62
Appendix 63
Methodology 63
About GlobalData 63
Contact Us 63
Disclaimer 63

List of Tables
Selecta Biosciences Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Selecta Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Selecta Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Selecta Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Selecta Biosciences Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Selecta Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Selecta Biosciences Raises USD38 Million in Series E Financing 12
Selecta Biosciences Raises More than USD20 Million in Venture Financing 14
Selecta Biosciences Raises USD4.4 Million in Venture Financing 16
Selecta Biosciences Raises USD6 Million in Venture Financing 17
Selecta Biosciences Raises USD5.3 Million in Venture Financing 18
Selecta Biosciences Secures US$47 Million In Series D Financing Round 19
Selecta Biosciences Enters into Research Agreement with Genethon 21
Selecta Biosciences and Juvenile Diabetes Research Foundation Enter into Co-Development Agreement with Sanofi 22
Juvenile Diabetes Research Foundation Enters Into Research Collaboration With Selecta Biosciences 23
Selecta Biosciences Enters into Licensing Agreement with National Cancer Institute 24
Spark Therapeutics Enters into Licensing Agreement with Selecta Biosciences 26
Selecta Biosciences Enters into Licensing Agreement with Massachusetts Eye and Ear Infirmary 28
Selecta Biosciences Enters into Licensing Agreement with 3SBio for Pegsiticase 29
Selecta Biosciences Exercises Option for Licensing Agreement with Sanofi 30
Selecta Biosciences Files Registration Statement to Raise Funds through Public Offering of Shares 31
Selecta Biosciences to Raise USD50 Million in Private Placement of Shares and Warrants 32
Selecta Biosciences to Raise USD5 Million in Private Placement of Shares 33
Selecta Biosciences Raises USD70 Million in IPO 35
Selecta Biosciences Inc, Key Competitors 37
Selecta Biosciences Inc, Key Employees 38
Selecta Biosciences Inc, Subsidiaries 39

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Selecta Biosciences Inc (SELB)-製薬・医療分野:企業M&A・提携分析(Selecta Biosciences Inc (SELB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆